Literature DB >> 31753799

Pan-specific and partially selective dye-labeled peptidic inhibitors of the polycomb paralog proteins.

Natalia Milosevich1, James McFarlane1, Michael C Gignac1, Janessa Li1, Tyler M Brown1, Chelsea R Wilson1, Lindsey Devorkin2, Caitlin S Croft1, Rebecca Hof1, Irina Paci1, Julian J Lum2, Fraser Hof3.   

Abstract

Epigenetic regulation of gene expression is in part controlled by post-translational modifications on histone proteins. Histone methylation is a key epigenetic mark that controls gene transcription and repression. There are five human polycomb paralog proteins (Cbx2/4/6/7/8) that use their chromodomains to recognize trimethylated lysine 27 on histone 3 (H3K27me3). Recognition of the methyllysine side chain is achieved through multiple cation-pi interactions within an 'aromatic cage' motif. Despite high structural similarity within the chromodomains of this protein family, they each have unique functional roles and are linked to different cancers. Selective inhibition of different CBX proteins is desirable for both fundamental studies and potential therapeutic applications. We report here on a series of peptidic inhibitors that target certain polycomb paralogs. We have identified peptidic scaffolds with sub-micromolar potency, and will report examples that are pan-specific and that are partially selective for individual members within the family. These results highlight important structure-activity relationships that allow for differential binding to be achieved through interactions outside of the methyllysine-binding aromatic cage motif.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CBX; Epigenetics; Methyllysine reader proteins; Peptidomimetics; Polycomb paralogs

Mesh:

Substances:

Year:  2019        PMID: 31753799     DOI: 10.1016/j.bmc.2019.115176

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Long Non-Coding RNA (lncRNA) RAMS11 Promotes Metastatis and Cell Growth of Prostate Cancer by CBX4 Complex Binding to Top2α.

Authors:  Zhixiong Zheng; Kaiyan Qiu; Weiwen Huang
Journal:  Cancer Manag Res       Date:  2021-02-02       Impact factor: 3.989

2.  Polycomb Paralog Chromodomain Inhibitors Active against Both CBX6 and CBX8*.

Authors:  Natalia Milosevich; Chelsea R Wilson; Tyler M Brown; Aktan Alpsoy; Sijie Wang; Katelyn E Connelly; Kirsten A D Sinclair; Felino R Ponio; Rebecca Hof; Emily C Dykhuizen; Fraser Hof
Journal:  ChemMedChem       Date:  2021-07-23       Impact factor: 3.540

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.